



TMEM39A and Human Diseases: A Brief Review

Quangdon Tran¹, Jisoo Park¹, Hyunji Lee¹, Youngeun Hong¹, Suntaek Hong²,
Sungjin Park¹, Jongsun Park¹ and Seon-Hwan Kim³

¹Department of Pharmacology and Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon, Korea

²Laboratory of Cancer Cell Biology, Department of Biochemistry, School of Medicine, Gachon University, Incheon, Korea

³Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Korea

Transmembrane Protein 39A (TMEM39A) is a member of TMEM family. The understanding about this protein is still limited. The earlier studies indicated that TMEM39A was a key mediator of autoimmune disease. TMEM39A seems to be involved in systemic lupus erythematosus and multiple sclerosis in numerous of populations. All of these works stop at insufficient information by using gene functioning methods such as: Genome-wide association studies (GWASs) and/or follow-up study. It is the fact that the less understood of TMEM39A actually is the attraction to the scientist in near future. In this review the current knowledge about TMEM39A and its possible roles in cell biology, physiology and pathology will be described.

Key words: Transmembrane proteins family, Multiple sclerosis, Systemic lupus erythematosus, Mitochondria, Mitophagy

INTRODUCTION

A transmembrane protein (TMEM) is a kind of integral membrane protein that exists in the total biological membrane. TMEM family is characterized by a presence of putative transmembrane domains (1). Many TMEMs works as gateways to allow the transport of specific elements through the biological membrane. TMEMs repeatedly experience important conformational changes to transfer a substance through the membrane. The understanding about functions and localization of this family is still unclear at the present moments.

Correspondence to: Jongsun Park, Department of Pharmacology and Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Korea
E-mail: insulin@cnu.ac.kr

Seon-Hwan Kim, Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon 35015, Korea
E-mail: neons@cnu.ac.kr

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

TRANSMEMBRANE PROTEIN FAMILY

TMEMs are predicted to be components of cellular membranes, such as mitochondrial membranes, endoplasmic reticulum (ER), lysosomes and golgi apparatus (2). Indeed, the localization of some protein members was proved by biochemical evidences, including TMEM22 (1) and TMEM45A (3). The functions of several TMEMs in cellular processing were also primarily described. TMEM16A, TMEM16F and TMEM16K were identified as the calcium-activated chloride channel (4,5). Remarkably, TMEM45A firstly was identified as effector of hypoxia condition in 2007 (6). Later on TMEM45A was reported to involve in epidermal keratinization (3). These biological functions implicated that TMEM45A may contribute to cancer development. Indeed, TMEM45A is essential for hypoxia-induced chemo-resistance in breast and liver cancers (7). Consistently, downregulation of TMEM45A suppressed many type of cancers by inhibiting the proliferation, migration and cell invasion. The progression of ductal carcinoma xenografts in situ to invasive breast cancer was dramatically increased by suppressing TMEM45A, which may due to its adhesion regulating effect (8). Similar effects were then observed in ovarian cancer (9) and glioma cells (10). Differential regulation of other TMEM members could be also observed in many cancers, such as

lymphomas (TMEM176) (11), colorectal cancer (TMEM25) (12), meningiomas (TMEM30B) (13), renal cell carcinoma (different TMEMs) (2,14-20), paragangliomas and pheochromocytomas (TMEM127) (21), suggesting that TMEM family is prominent group for further cancer research. However there are vast different characteristic and localization between the members of TMEMs. Thus, the biological functions of each candidate member need to be elucidated in detail.

TMEM39A- THE FURTHER FOCUS

The function of TMEM39A is poorly identified in the member of TMEMs. It contains 488 amino acid and 8 transmembrane helix segments in its sequence (Based on UniProt database; Fig. 1A). Employing Singer's classification of proteins, TMEM39A is classified as type 3-transmembrane protein (Fig. 1B) (22). The function of TMEM39A was first revealed in 2010 by the international multiple sclerosis genetics consortium (23). TMEM39A was identified as susceptibility loci of multiple sclerosis. This discovery was again confirmed by Varade *et al* (24). Multiple sclerosis is the most common neurological disease among young adults, with onset at a mean age of 30 years. It is an autoimmune condition of the central nervous system affecting over 2 million individuals world-wide (23,24). By also using a




Fig. 1. TMEM39A is predicted as type III membrane protein. (A) Schematic of TMEM39A topology analyzing in UniProt database. TMEM39A contains eight transmembrane domains starting at residues: 72, 110, 154, 182, 287, 319, 420, 446. (B) The topography of the four main types (I-IV) of integral membrane proteins. The external and cytoplasmic surfaces of the membrane are designated by outer and inner respectively. (Adopted from (22)).

genome-wide association (GWA) study, recent studies indicated that TMEM39A involved in Erythematosus, which is considered as autoimmune disease (25-27). These impli-




Fig. 2. The network showing interactions of TMEM39A with its interactors. TMEM39A was found to be interacted with several protein baits (28). The major function and localization of each interactor were also investigated. Among seven interactor, five proteins including Zaccn, Tnfsf13B, IL9R, CHRNA9 and HTR3C are located in cell membrane. Nesprin-4 locates to nuclear outer membrane and BTNL8 is just predicted to be in membrane. Regarding to the functions of those interactors, there are 4 proteins involved in immunology including Tnfsf13B, IL9R, BTNL8, and HTR3C. Other proteins have the following function; Zaccn - ion channel, CHRNA9 - neuron development, Nesprin-4 - nuclear positioning. (BTNL8: Butyrophilin-like protein 8, CHRNA9: Neuronal acetylcholine receptor subunit alpha-9, HTR3C: 5-hydroxytryptamine receptor 3C, IL9R: Interleukin-9 receptor, Tnfsf13b: Tumor necrosis factor ligand superfamily member 13B, Zaccn: Zinc-activated ligand-gated ion channel).

cated that TMEM39A had an important contribution in immune system such as: inflammation, dysregulated type 1 interferon responses, and autoantibodies directed to the nuclear compartment which were characteristics of erythematosis. TMEM39A was found to be bound to seven baits (Fig. 2) (28). Among all the baits, Tumor necrosis factor ligand superfamily member 13B (Tnfsf13B), Butyrophilin-like protein 8 (BTNL8) and 5-hydroxytryptamine receptor 3C (HTR3C), Interleukin-9 receptor (IL9R) were involved in immune system. Thus the further study is required to demonstrate the molecular mechanism of TMEM39A in immune response.

TMEM39A was significantly changed in sclerosis-a neurological disease. Cholinergic receptor nicotinic alpha 9 subunit (CHRNA9), an interactor of TMEM39A (29), also functioned in neuronal activity. In brain, the functions, dynamics and homeostasis of mitochondria are really important and associating with several neuronal disorder diseases. Mitochondria dose not only provide ATP but also perform a variety of roles in processes such as the transduction of metabolic and stress signals. Thereby mitochondria was a factor deciding the cell fate. The quality and quantity controls of mitochondrial thus were highlighted. Mitophagy, a key process to remove damaged mitochondria, was well known to be regulated by Pink/Parkin pathway which linked to the neurodegenerative diseases. Mutations in these protein encoded-genes defected mitophagy leading to accumulation of damage mitochondria, resulting in neuronal cell death (30). Taken these evidences raised a question that: is there any contribution of TMEM39A in mitochondria, mitophagy and other molecular signaling in neuron? Indeed, image-based genome-wide siRNA screen study showed that TMEM39 was potential factor involved in Parkin-mediated mitophagy (31). However the molecular mechanism for this phenomenon has not been provided yet. In addition, it has been found that TMEM39A was mutated in breast cancer (32). Moreover, mitophagy and mitochondria were considered as the important modulators of tumorigenesis and development (33-35). Note that in TMEM family, TMEM59 was known as regulator of neuron stem cell during differentiation (36) as well as an Alzheimer's related protein (37,38). Interestingly, Emilio et al. showed that TMEM59 binds to ATG16L and promotes local activation LC3 (39). This indicated for a connection between a trans-membrane protein with autophagy and neuronal disease that can also be happened in case of TMEM39A. From these all information, the relationship between TMEM39A and brain tumor-GBM, autophagy may become a good point for further study.

In other aspect, the discovery of TMEM39A role in mitochondria pointed that intracellular location of TMEM39A is now also in needed and mitochondria might be a possibility. However five of seven interactors identified by Huntlin *et al.* (28) were cell membrane proteins or were predicted to be cell membrane proteins (Fig. 2). This impli-

cates that TMEM39A may be in cell membrane and thus may have more change to interact with those interactors.

CONCLUSION REMARKS

The function of TMEM39A is poorly understood. There is no biochemical evidence to bring this protein into the brightness. However, the genetic studies have discovered that TMEM39A may contribute to Multiple Sclerosis and Erythematosis, the autoimmune diseases. Base on all of our knowledge about TMEM39A, this review has described and connected its characteristics with cellular biology topics, therefore providing some promising points for TMEM39A study in future:

1. The molecular mechanism of TMEM39A in regulating the autoimmune diseases. Investigation of some of TMEM39A interactors such as Tnfsf13B, BTNL8 and HTR3C, IL9R might provide the interesting results with TMEM39A in autoimmune diseases.
2. The function of TMEM39A in mitochondria and mitophagy has been suggested. Thus, the further study on the effects of TMEM39A on mitophagy in neurobiology and brain cancer will be required.
3. The exact localization of TMEM39A is urgently required to investigate the function of TMEM39A. TMEM39A might localize to plasma membrane since most of its interactors are plasma membrane proteins. However mitochondrial localization of TMEM39A is also possible, due to the effects of TMEM39A on mitophagy.

ACKNOWLEDGMENTS

This work was financially supported by research fund of Chungnam National University in 2014 (Seon-Hwan Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2012M3A9B6055302, NRF-2014R1A1A3050752, NRF-2015R1A2A2A01003597, NRF-2015R1D1A3A01015694).

Received April 18, 2017; Revised June 13, 2017; Accepted June 13, 2017

REFERENCES

1. Dobashi, S., Katagiri, T., Hirota, E., Ashida, S., Daigo, Y., Shuin, T., Fujioka, T., Miki, T. and Nakamura, Y. (2009) Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells. *Oncol. Rep.*, **21**, 305-312.
2. Wrzesinski, T., Szelag, M., Cieslikowski, W.A., Ida, A., Giles, R., Zdro, E., Szumska, J., Pozniak, J., Kwias, Z., Bluysen, H.A. and Wesoly, J. (2015) Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. *BMC Cancer*, **15**, 518.
3. Hayez, A., Malaisse, J., Roegiers, E., Reynier, M., Renard, C., Haftek, M., Geenen, V., Serre, G., Simon, M., de Rouvroit,

- C.L., Michiels, C. and Poumay, Y. (2014) High TMEM45A expression is correlated to epidermal keratinization. *Exp. Dermatol.*, **23**, 339-344.
4. Ferrera, L., Caputo, A. and Galletta, L.J. (2010) TMEM16A protein: A new identity for Ca²⁺-dependent Cl⁻ channels. *Physiology (Bethesda)*, **25**, 357-363.
 5. Ishihara, K., Suzuki, J. and Nagata, S. (2016) Role of Ca²⁺ in the Stability and Function of TMEM16F and 16K. *Biochemistry*, **55**, 3180-3188.
 6. Martin-Rendon, E., Hale, S.J., Ryan, D., Baban, D., Forde, S.P., Roubelakis, M., Sweeney, D., Moukayed, M., Harris, A.L., Davies, K. and Watt, S.M. (2007) Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. *Stem Cells*, **25**, 1003-1012.
 7. Flamant, L., Roegiers, E., Pierre, M., Hayez, A., Sterpin, C., De Backer, O., Arnould, T., Poumay, Y. and Michiels, C. (2012) TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. *BMC Cancer*, **12**, 391.
 8. Lee, S., Stewart, S., Nagtegaal, I., Luo, J., Wu, Y., Colditz, G., Medina, D. and Allred, D.C. (2012) Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. *Cancer Res.*, **72**, 4574-4586.
 9. Guo, J., Chen, L., Luo, N., Yang, W., Qu, X. and Cheng, Z. (2015) Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. *Oncol. Rep.*, **33**, 3124-3130.
 10. Sun, W., Qiu, G., Zou, Y., Cai, Z., Wang, P., Lin, X., Huang, J., Jiang, L., Ding, X. and Hu, G. (2015) Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells. *Int. J. Clin. Exp. Pathol.*, **8**, 12657-12667.
 11. Cuajungco, M.P., Podevin, W., Valluri, V.K., Bui, Q., Nguyen, V.H. and Taylor, K. (2012) Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology. *Acta Histochem.*, **114**, 705-712.
 12. Hrasovec, S., Hauptman, N., Glavac, D., Jelenc, F. and Ravnik-Glavac, M. (2013) TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer. *Dis. Markers*, **34**, 93-104.
 13. Perez-Magan, E., Campos-Martin, Y., Mur, P., Fiano, C., Ribalta, T., Garcia, J.F., Rey, J.A., Rodriguez de Lope, A., Mollejo, M. and Melendez, B. (2012) Genetic alterations associated with progression and recurrence in meningiomas. *J. Neuropathol. Exp. Neurol.*, **71**, 882-893.
 14. Beroukhi, R., Brunet, J.P., Di Napoli, A., Mertz, K.D., Seeley, A., Pires, M.M., Linhart, D., Worrell, R.A., Moch, H., Rubin, M.A., Sellers, W.R., Meyerson, M., Linehan, W.M., Kaelin, W.G., Jr. and Signoretti, S. (2009) Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Res.*, **69**, 4674-4681.
 15. Cifola, I., Spinelli, R., Beltrame, L., Peano, C., Fasoli, E., Ferrero, S., Bosari, S., Signorini, S., Rocco, F., Perego, R., Proserpio, V., Raimondo, F., Mocarelli, P. and Battaglia, C. (2008) Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. *Mol. Cancer*, **7**, 6.
 16. Gumz, M.L., Zou, H., Kreinest, P.A., Childs, A.C., Belmonte, L.S., LeGrand, S.N., Wu, K.J., Luxon, B.A., Sinha, M., Parker, A.S., Sun, L.Z., Ahlquist, D.A., Wood, C.G. and Copland, J.A. (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. *Clin. Cancer Res.*, **13**, 4740-4749.
 17. Jones, J., Otu, H., Spentzos, D., Kolia, S., Inan, M., Beecken, W.D., Fellbaum, C., Gu, X., Joseph, M., Pantuck, A.J., Jonas, D. and Libermann, T.A. (2005) Gene signatures of progression and metastasis in renal cell cancer. *Clin. Cancer Res.*, **11**, 5730-5739.
 18. Tun, H.W., Marlow, L.A., von Roemeling, C.A., Cooper, S.J., Kreinest, P., Wu, K., Luxon, B.A., Sinha, M., Anastasiadis, P.Z. and Copland, J.A. (2010) Pathway signature and cellular differentiation in clear cell renal cell carcinoma. *PLoS ONE*, **5**, e10696.
 19. Wang, Y., Roche, O., Yan, M.S., Finak, G., Evans, A.J., Metcalf, J.L., Hast, B.E., Hanna, S.C., Wondergem, B., Furge, K.A., Irwin, M.S., Kim, W.Y., Teh, B.T., Grinstein, S., Park, M., Marsden, P.A. and Ohh, M. (2009) Regulation of endocytosis via the oxygen-sensing pathway. *Nat. Med.*, **15**, 319-324.
 20. Dalgliesh, G.L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., Teague, J., Andrews, J., Barthorpe, S., Beare, D., Buck, G., Campbell, P.J., Forbes, S., Jia, M., Jones, D., Knott, H., Kok, C.Y., Lau, K.W., Leroy, C., Lin, M.L., McBride, D.J., Maddison, M., Maguire, S., McLay, K., Menzies, A., Mironenko, T., Mulderrig, L., Mudie, L., O'Meara, S., Pleasance, E., Rajasingham, A., Shepherd, R., Smith, R., Stebbings, L., Stephens, P., Tang, G., Tarpey, P.S., Turrell, K., Dykema, K.J., Khoo, S.K., Petillo, D., Wondergem, B., Anema, J., Kahnski, R.J., Teh, B.T., Stratton, M.R. and Futreal, P.A. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature*, **463**, 360-363.
 21. Abermil, N., Guillaud-Bataille, M., Burnichon, N., Venisse, A., Manivet, P., Guignat, L., Drui, D., Chupin, M., Josseume, C., Affres, H., Plouin, P.F., Bertherat, J., Jeunemaitre, X. and Gimenez-Roqueplo, A.P. (2012) TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. *J. Clin. Endocrinol. Metab.*, **97**, E805-E809.
 22. Singer, S.J. (1990) The structure and insertion of integral proteins in membranes. *Annu. Rev. Cell Biol.*, **6**, 247-296.
 23. International Multiple Sclerosis Genetics Consortium (IMSGC) (2010) Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. *Hum. Mol. Genet.*, **19**, 953-962.
 24. Varade, J., Comabella, M., Ortiz, M.A., Arroyo, R., Fernandez, O., Pinto-Medel, M.J., Fedetz, M., Izquierdo, G., Lucas, M., Gomez, C.L., Rabasa, A.C., Alcina, A., Matesanz, F., Alloza, I., Antiguada, A., Garcia-Barcina, M., Otaegui, D., Olascoaga, J., Saiz, A., Blanco, Y., Montalban, X., Vandembroeck, K. and Urcelay, E. (2012) Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. *Mult. Scler.*, **18**, 959-965.
 25. Sheng, Y.J., Xu, J.H., Wu, Y.G., Zuo, X.B., Gao, J.P., Lin, Y., Zhu, Z.W., Wen, L.L., Yang, C., Liu, L., Cheng, Y.Y., Chang, Y., Yang, L.L., Zhou, F.S., Tang, X.F., Zheng, X.D., Yin, X.Y., Tang, H.Y., Sun, L.D., Cui, Y., Yang, S. and Zhang, X.J. (2015) Association analyses confirm five susceptibility loci

- for systemic lupus erythematosus in the Han Chinese population. *Arthritis Res. Ther.*, **17**, 85.
26. You, Y., Zhai, Z.F., Chen, F.R., Chen, W. and Hao, F. (2015) Autoimmune risk loci of IL12RB2, IKZF1, XKR6, TMEM39A and CSK in Chinese patients with systemic lupus erythematosus. *Tissue Antigens*, **85**, 200-203.
 27. Lessard, C.J., Adrianto, I., Ice, J.A., Wiley, G.B., Kelly, J.A., Glenn, S.B., Adler, A.J., Li, H., Rasmussen, A., Williams, A.H., Ziegler, J., Comeau, M.E., Marion, M., Wakeland, B.E., Liang, C., Ramos, P.S., Grundahl, K.M., Gallant, C.J., Alarcon-Riquelme, M.E., Alarcon, G.S., Anaya, J.M., Bae, S.C., Boackle, S.A., Brown, E.E., Chang, D.M., Cho, S.K., Criswell, L.A., Edberg, J.C., Freedman, B.I., Gilkeson, G.S., Jacob, C.O., James, J.A., Kamen, D.L., Kimberly, R.P., Kim, J.H., Martin, J., Merrill, J.T., Niewold, T.B., Park, S.Y., Petri, M.A., Pons-Estel, B.A., Ramsey-Goldman, R., Reveille, J.D., Scofield, R.H., Song, Y.W., Stevens, A.M., Tsao, B.P., Vila, L.M., Vyse, T.J., Yu, C.Y., Guthridge, J.M., Kaufman, K.M., Harley, J.B., Wakeland, E.K., Langefeld, C.D., Gaffney, P.M., Montgomery, C.G. and Moser, K.L.; BIOLUPUS Network; GENLES Network. (2012) Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. *American Journal of Human Genetics*, **90**, 648-660.
 28. Huttlin, E.L., Ting, L., Bruckner, R.J., Gebreab, F., Gygi, M.P., Szpyt, J., Tam, S., Zarraga, G., Colby, G., Baltier, K., Dong, R., Guarani, V., Vaites, L.P., Ordureau, A., Rad, R., Erickson, B.K., Wuhr, M., Chick, J., Zhai, B., Kolippakkam, D., Mintseris, J., Obar, R.A., Harris, T., Artavanis-Tsakonas, S., Sowa, M.E., De Camilli, P., Paulo, J.A., Harper, J.W. and Gygi, S.P. (2015) The bioplex network: a systematic exploration of the human interactome. *Cell*, **162**, 425-440.
 29. Lips, K.S., Pfeil, U. and Kummer, W. (2002) Coexpression of alpha 9 and alpha 10 nicotinic acetylcholine receptors in rat dorsal root ganglion neurons. *Neuroscience*, **115**, 1-5.
 30. Son, J.H., Shim, J.H., Kim, K.H., Ha, J.Y. and Han, J.Y. (2012) Neuronal autophagy and neurodegenerative diseases. *Exp. Mol. Med.*, **44**, 89-98.
 31. Orvedahl, A., Sumpter, R., Jr., Xiao, G., Ng, A., Zou, Z., Tang, Y., Narimatsu, M., Gilpin, C., Sun, Q., Roth, M., Forst, C.V., Wrana, J.L., Zhang, Y.E., Luby-Phelps, K., Xavier, R.J., Xie, Y. and Levine, B. (2011) Image-based genome-wide siRNA screen identifies selective autophagy factors. *Nature*, **480**, 113-117.
 32. Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S.D., Willis, J., Dawson, D., Willson, J.K., Gazdar, A.F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B.H., Bachman, K.E., Papadopoulos, N., Vogelstein, B., Kinzler, K.W. and Velculescu, V.E. (2006) The consensus coding sequences of human breast and colorectal cancers. *Science*, **314**, 268-274.
 33. Palikaras, K., Lionaki, E. and Tavernarakis, N. (2016) Mitophagy: In sickness and in health. *Mol. Cell. Oncol.*, **3**, e1056332.
 34. Senft, D. and Ronai, Z.A. (2016) Regulators of mitochondrial dynamics in cancer. *Curr. Opin. Cell Biol.*, **39**, 43-52.
 35. Bernardini, J.P., Lazarou, M. and Dewson, G. (2016) Parkin and mitophagy in cancer. *Oncogene*, **36**, 1315-1327.
 36. Zhang, L., Ju, X., Cheng, Y., Guo, X. and Wen, T. (2011) Identifying Tmem59 related gene regulatory network of mouse neural stem cell from a compendium of expression profiles. *BMC Syst. Biol.*, **5**, 152.
 37. Ullrich, S., Munch, A., Neumann, S., Kremmer, E., Tatzelt, J. and Lichtenthaler, S.F. (2010) The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein. *J. Biol. Chem.*, **285**, 20664-20674.
 38. Guttula, S.V., Allam, A. and Gumpeny, R.S. (2012) Analyzing microarray data of Alzheimer's using cluster analysis to identify the biomarker genes. *Int. J. Alzheimers Dis.*, **2012**, 649456.
 39. Boada-Romero, E., Letek, M., Fleischer, A., Pallauf, K., Ramon-Barros, C. and Pimentel-Muinos, F.X. (2013) TMEM59 defines a novel ATG16L1-binding motif that promotes local activation of LC3. *EMBO J.*, **32**, 566-582.